+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Long-term results with MACOP-B in the treatment of aggressive non-Hodgkin's lymphomas. The experience in Brazil

Long-term results with MACOP-B in the treatment of aggressive non-Hodgkin's lymphomas. The experience in Brazil

American Journal of Clinical Oncology 17(4): 323-327

From October 1984 to December 1989, 59 patients with aggressive non-Hodgkin's lymphomas (diffuse mixed, diffuse large cell, and immunoblastic) were treated with MACOP-B. All patients were previously untreated and most of them had advanced disease. Complete response (CR) was observed in 66%. Actuarial overall survival, failure-free survival (FFS), and relapse-free survival at 8 years were 54%, 52%, and 81%, respectively, with a median follow-up of 76 months (range: 28-92 months). The presence of B symptoms influenced significantly the CR rate, while FFS was affected by B symptoms, bone marrow involvement, and number of extranodal sites. Toxicity was high, with mucositis grade 2 or 3 occurring in 70%, leukopenia grades 3 or 4 in 80%, and death in 11.8% of the patients. MACOP-B was active in the treatment of aggressive non-Hodgkin's lymphomas, mainly in patients with few poor-prognosis factors, but other less toxic regimens would be more appropriate for this population. For poor-prognosis patients, new therapeutic modalities are necessary.

(PDF emailed within 1 workday: $29.90)

Accession: 008972262

Download citation: RISBibTeXText

PMID: 7519390

Related references

Long-term results with MACOP-B and radiation therapy for aggressive lymphomas. Onkologie 24 Suppl 1(): 49-58, 2001

Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas. Journal of Clinical Oncology 8(1): 94-102, 1990

CHOP vs ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: Long-term results of a multicenter randomized trial. European Journal of Haematology 57(5): 377-383, 1996

The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. European Journal of Haematology 76(3): 217-229, 2006

How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?. Haematologica 84(11): 996-1001, 1999

ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leukemia & Lymphoma 17(3-4): 313-320, 1995

CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). European Journal of Haematology 57(5): 377-383, 1996

Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. International Journal of Hematology 91(1): 78-86, 2010

Long-term results of treatment of aggressive non-Hodgkin lymphoma in the elderly (70 years or older). DMW (Deutsche Medizinische Wochenschrift) 123(8): 205-211, 1998

Macop b chemotherapy for the treatment of aggressive non hodgkin's lymphoma. Leukemia and Lymphoma 6(4-5): 357-361, 1992

The treatment of large-cell non-Hodgkin's lymphomas with the MACOP-B protocol. Medicina Clinica 97(14): 521-525, 1991

MACOP-B vs F-MACHOP in the treatment of high-grade non-Hodgkin's lymphomas. Leukemia 5 Suppl 1: 74-78, 1991

Treatment of an aggressive non-Hodgkin's lymphoma during pregnancy with MACOP-B chemotherapy. Medical and Pediatric Oncology 18(2): 143-145, 1990

Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an "equalizer" in the MInT (MABTHERA International Trial Group) study. Journal of Clinical Oncology 23(16_suppl): 6529-6529, 2016

Intensive treatment of AIDS-related non-Hodgkin's lymphomas with MACOP-B protocol. European Journal of Haematology 54(2): 73-77, 1995